Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Sixteen healthy male volunteers who smoked at least 20 cigarettes a day and satisfied DSM‐IIIR criteria for nicotine dependence were recruited to investigate the possible effects of a selective 5HT‐3 receptor antagonist (BRL 46470A) on acute nicotine withdrawal. The study was of a double‐blind, placebo‐controlled, four‐way crossover design using two doses of BRL 46470A (0.1 and 10 μg) and one dose of lorazepam (1 mg). Outcome measures included visual analogue ratings for nicotine withdrawal and a battery of psychological performance tests. Except for an effect of BRL 46470A (0.1 μg) to decrease subjective rating of confusion, none of the drug treatments attenuated subjective measures of nicotine withdrawal. Lorazepam significantly impaired performance on all three tests of neuropsychological function, but BRL 46470A was without effect on these measures. Copyright © 1993 John Wiley & Sons, Ltd.

Original publication




Journal article


Human Psychopharmacology: Clinical and Experimental

Publication Date





345 - 349